The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community.
Debra A. Patt
Employment or Leadership Position - US Oncology
Janet L. Espirito
No relevant relationships to disclose
Brian Turnwald
No relevant relationships to disclose
J. Russell Hoverman
Employment or Leadership Position - Texas Oncology; US Oncology
Consultant or Advisory Role - United Healthcare
Marcus A. Neubauer
Employment or Leadership Position - US Oncology
Thomas H. Cartwright
Consultant or Advisory Role - Amgen; Genentech; Lilly; Sanofi
Honoraria - Amgen; Lilly; Roche; Sanofi
Leslie T. Busby
Employment or Leadership Position - US Oncology
Barry Don Brooks
Employment or Leadership Position - US Oncology
Honoraria - Eisai
Mark A. Sitarik
Employment or Leadership Position - US Oncology
Michael A. Kolodziej
Employment or Leadership Position - US Oncology
Roy A. Beveridge
Employment or Leadership Position - US Oncology